European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (T
Go back to European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (T| Merck & Co. (NYSE: MRK) | Delayed: 147.15 +2.24 (1.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.91 | 52 Week High | $65.46 | |||
| Open | $145.74 | 52 Week Low | $47.97 | |||
| Day High | $147.65 | P/E | 100.10 | |||
| Day Low | $145.32 | EPS | $1.47 | |||
| Volume | 11,063,719 | |||||
